ESLA
What one share of Estrella Immunopharma holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company developing T-cell therapies to address treatment challenges for patients with cancers and autoimmune diseases. Our strategy is to harness the evolutionary power of the human immune system to provide patients with potentially safer, more efficacious T-cell therapies compared to traditional CAR-T therapies.
Estrella Immunopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.25 |
|---|---|
| Cash and investments | $0.00 |
| Book value | −$0.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$0.21 | — | −$0.27 | — | −$0.71 |
| 2023 | — | −$36.35 | — | −$4.37 | — | — |
| 2024 | — | −$0.27 | — | −$0.59 | — | $0.12 |
| 2025 | — | −$0.35 | — | −$0.05 | — | −$0.24 |